3SBio Signs Deal For Isotechnika's Transplant/Immune System Drug Voclosporin
This article was originally published in The Pink Sheet Daily
Executive Summary
The deal was announced less than three weeks after U.S. FDA requested an additional Phase III trial for an oral voclosporin used in uveitis therapy.
You may also be interested in...
Last-Minute Cancellation Of Advisory Panel Meeting Throws Future of Luveniq Into Doubt
"Several outstanding issues" forced FDA to cancel the meeting, the agency said.
Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.
Bayer/J&J's Xarelto Approval For Stroke Prevention Sets Up Marketing Battle With Pradaxa
With an unrestricted label and once-daily dosing, rivaroxaban will do battle with Boehringer-Ingelheim's dabigatran, which is dosed twice a day but can claim superior efficacy to warfarin in the atrial fibrillation population.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports
New to Pink Sheet?
Start a free trial today!
Register for our free email digests:
Register for our free email digests: